Article Sidebar

pdf
Date Published: 04/11/2025
Abstract Views: 123
Views pdf: 56
DOI: https://doi.org/10.51298/vmj.v555i2.16057
Issue
Vol. 555 No. 2 (2025)
Section
Các bài báo
How to Cite
Lê, T. D., Tạ, V. T., & Lê, T. U. (2025). IMMUNOHISTOCHEMICAL CHARACTERISTICS OF DUCTAL CARCINOMA IN SITU OF THE BREAST. Vietnam Medical Journal, 555(2). https://doi.org/10.51298/vmj.v555i2.16057

IMMUNOHISTOCHEMICAL CHARACTERISTICS OF DUCTAL CARCINOMA IN SITU OF THE BREAST

Thị Duyên Lê, Văn Tờ Tạ, Thị Uyên Lê

Main Article Content

Abstract

Objective: Determine the expression rates of ER, PR, HER2, and Ki67 and correlate them with histopathological features in ductal carcinoma in situ (DCIS) at the Department of Pathology -Molecular Biology, K Hospital. Subjects and Methods: A cross-sectional descriptive study was conducted on 210 cases of DCIS diagnosed on surgical specimens from 2022 to 2024. Data were analyzed using SPSS version 20.0 with Chi-square and Fisher’s Exact tests; p-values less than 0.05 were considered statistically significant. Results: The positive expression rates of ER and PR were 61.4% and 49%, respectively, predominantly observed in DCIS lesions with low to intermediate nuclear grade, cribriform or mixed architectural patterns, and absence of comedo necrosis (p < 0.001). Conversely, HER2 positivity (55.2%) and high Ki-67 index (59%) were significantly associated with high-grade lesions, solid or micropapillary types, and presence of comedo necrosis (p< 0.001). Conclusion: ER, PR, HER2 and Ki-67 are statistically significantly associated with histological grade, histological type, and comedo necrosis (p < 0.001

Article Details

Keywords

DCIS, ER, PR, HER2, Ki-67.

References

Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2022.2.
2. Tan PH, Ellis I, Allison K, et al. The 2019 World Health Organization classification of tumours of the breast. Histopathology. 2020
3. Scripcaru G, Zardawi IM. Mammary ductal carcinoma in situ: a fresh look at architectural patterns. Int J Surg Oncol. 2012;2012:979521.
4. Kim JY, Park K, Kang G, Kim HJ, Gwak G, Shin YJ. Predictors of recurrent ductal carcinoma in situ after breast-conserving surgery. J Breast Cancer. 2016;19(2):185–190.
5. Yang L, Shen M, Qiu Y, Tang T, Bu H. Molecular subtyping reveals uniqueness of prognosis in breast ductal carcinoma in situ patients with lumpectomy. The Breast. 2022;64:1–6.
6. Barnes NLP, Boland GP, Davenport A, Knox WF, Bundred NJ. Relationship between hormone receptor status and tumour size, grade and comedo necrosis in ductal carcinoma in situ. Br J Surg. 2005
7. Sathvik G, V P, Joseph LD, Challa CB. Spectrum of ductal carcinoma in situ (DCIS) lesions of the breast: From morphology to molecular characteristics. Cureus. 2024;16(9): e69929.